Innovate UK

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Nuclera specializes in providing a protein prototyping system designed to enhance drug discovery by making proteins readily accessible to researchers. The company's eProtein Discovery system enables scientists to quickly produce and evaluate proteins, thus accelerating their research efforts. Nuclera's automated platform delivers reliable, high-quality, and soluble proteins within a specified timeframe, facilitating the scale-up of protein projects. The integration of technology, including cell-free protein synthesis and digital microfluidics on smart cartridges, allows for efficient, high-throughput access to proteins. This streamlined approach supports researchers in advancing their protein projects more rapidly and effectively.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.

BSF Enterprise is focused on advancing biotechnology solutions through a strategic approach of acquiring businesses within the biotech, marketing, and e-commerce sectors. The company specializes in cell-based tissue engineering, which enables the development of lab-grown products such as cultured meat, lab-grown leather, human corneas, collagen, and skin substitutes. By leveraging these innovative technologies, BSF Enterprise aims to facilitate sustainable solutions across multiple industries, contributing to significant advancements in the field of biotechnology.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

PulmoBiomed is a developer of innovative sampling technology that offers a non-invasive method for clinicians and researchers to collect biological samples. The company's primary product is a passive fluid aerosol sampler designed to capture exhaled breath condensate and environmental particles, effectively segregating them by size. This technology addresses critical challenges in sample collection, such as preventing contamination and loss, while ensuring the generation of highly reproducible data with digital molecular precision. By focusing on metabolomic profiling and biological agent capture, PulmoBiomed aims to enhance the accuracy and reliability of respiratory diagnostics and research.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

We are a team of matrix biologists, cancer scientists, toxicologists, and biomaterial engineers who have worked together to develop an innovative, animal-free solution for 3D cell culture. We have done this with the support of the NC3Rs, BBSRC, and EPSRC. By combining the skills and expertise of individuals across a broad range of scientific backgrounds we are able to develop technologies that address a variety of unmet challenges in 3D in vitro modelling. Our mission is to provide researchers a better way to model development and disease that is more reproducible, reliable, and ethical. To learn more, visit www.peptimatrix.com

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Concert Bio helps businesses create optimal microbial communities.

The National Biofilms Innovation Centre (NBIC) is the central hub where academia, industry, government, and public policy come together to tackle the grand challenges biofilms present, impacting ~$5 trillion in global economic activity, from food and health to ships, clean water and energy. Funded by the BBSRC, Innovate UK and Hartree Centre, our mission is to establish a network of research and innovation capacity to catalyse partnerships with industry to achieve breakthrough innovations and impact – from industry products and solutions to services and spinouts. We aim to bring together researchers and industry to explore unmet needs and exchange ideas, problems and solutions through roadmaps, workshops and conferences. We plan to invest in future scientists through our PhD and Post-Doc programs, and entrepreneurial training, to grow their expertise, help them better understand the commercial environment and encourage new start-ups.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Awakn Life Sciences is a biotechnology company dedicated to developing and delivering psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company's team comprises chemists, scientists, psychiatrists, and psychologists who are working on the next generation of psychedelic drugs and therapies. By addressing AUD, a condition that affects millions worldwide and for which existing treatments are often insufficient, Awakn seeks to provide innovative therapeutic solutions for individuals struggling with addiction.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies to treat hearing loss. Founded in 2018, the company specializes in advanced stem cell technology that aims to repair damaged or dead sensory cells in the inner ear, specifically targeting sensorineural hearing loss. By restoring the cytoarchitecture of the inner ear, Rinri Therapeutics seeks to enable medical professionals to effectively restore hearing for affected patients.

CryoLogyx is an early-stage biotechnology company focused on advancing cell cryopreservation technology to enhance drug discovery processes. By employing innovative methods that utilize cryoprotectants, CryoLogyx transforms the freezing, storage, and transportation of cells. This proprietary technology ensures the delivery of viable, ready-to-use cells and cell therapies, allowing healthcare researchers to access these resources in the desired format. The company's approach aims to improve the efficiency and effectiveness of cell-based research in the fields of medicine discovery, diagnostics, and cell therapy.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Aramune Technologies focuses on creating natural, plant-derived feed materials that can be integrated with conventional animal feeds to replace antimicrobial agents and foster growth. The company is dedicated to developing infection prevention technologies that offer sustainable alternatives to harmful ingredients in both animal and consumer healthcare products. Through laboratory-scale isolation, Aramune generates a natural, orally available compound that is free of endotoxins and non-toxic. This innovation aims to prevent infections in livestock, companion animals, and humans, thereby helping farmers reduce the incidence of diseases and infections in their animals.

SilviBio is a company focused on enhancing the sustainability of tree growth through innovative seed enhancement technology. It develops products aimed at reducing seed losses, which pose challenges for forestry organizations striving to meet government tree planting goals. By creating a coating for seeds that improves moisture absorption and retention, SilviBio enables growers to achieve higher germination rates, particularly in dry conditions. This technology not only supports forestry efforts but also has applications in the agriculture sector, contributing to improved yield outcomes.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with an additional location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design and development of innovative anti-infective therapies for medically unmet diseases. Its product pipeline includes Novexatin, a cationic antifungal peptide for treating onychomycosis, and Lynovex, a dual-therapy for cystic fibrosis-related lung diseases. Additionally, NovaBiotics offers other antifungal peptides such as Novamycin for conditions like aspergillosis and cryptococcosis, as well as Novarifyn, an antibacterial peptide targeting bacterial infections. The company’s proprietary anti-infective peptide platform allows for the development of both antifungal and antibacterial candidates, addressing serious health challenges related to drug-resistant infections.

DIOSynVax is a vaccine antigen design company that focuses on accelerating vaccine development to enhance protection against both existing and emerging pathogens. By utilizing innovative technology, DIOSynVax digitally designs, optimizes, and synthesizes vaccines, leading to significant advancements in immunization against diseases such as influenza, COVID-19, and viral hemorrhagic fevers. The company's approach aims to improve the efficacy of vaccines, enabling healthcare professionals to treat patients more effectively and facilitate quicker recovery from various viral infections.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain, and France. The company leverages proprietary technologies to enhance the body's natural ability to heal, focusing on the development of advanced cell-based therapeutics for serious diseases. Ixaka's innovative approaches include concentrated multi-cell therapies and targeted nanoparticles that aim to deliver curative cells directly to the site of disease and improve their therapeutic efficacy. This platform has potential applications across a variety of conditions, including oncology, cardiovascular, neurological, ocular diseases, and genetic disorders. The ultimate goal of Ixaka's therapies is to reduce pain, improve mobility, and enhance overall patient outcomes.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Aglaris is focused on developing automated cell culture bioreactors for the mass production of human stem cells. The company designs equipment that simplifies cell and tissue culture, enhancing the reliability and speed of the production process. By automating and controlling these processes, Aglaris aims to produce high-quality cells and tissues that can significantly advance regenerative medicine and cell therapies. Their technology is unique and protected by international patents, which helps minimize the need for human intervention and reduces contamination risks associated with cell handling. This innovation enables bio-entrepreneurs to generate new cells and improve their quality effectively.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

Bionema Limited is a company based in Swansea, United Kingdom, that focuses on the research, development, and commercialization of biopesticides and related products for the horticulture, turf, landscape, and forestry sectors. Established in 2012, Bionema specializes in creating chemical-free, organic crop protection solutions aimed at reducing the reliance on synthetic pesticides. The company develops natural products that protect crops from insect damage, thereby enhancing food security and increasing crop yields. In addition to biopesticides, Bionema also offers biostimulants and biofertilizers, promoting sustainable agriculture through the use of environmentally-friendly microorganisms. The company provides specialized bio-control products and training to improve product efficacy, helping farmers and businesses achieve effective pest management while fostering agricultural sustainability and environmental health.

Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, primarily targeting the life science research community. Ubiquigent focuses on protein degradation and the ubiquitin signaling systems, providing services that support drug discovery efforts aimed at developing novel deubiquitylase (DUB) enzyme inhibitors. The company works closely with academic researchers and pharmaceutical scientists, aiding in the exploration of therapeutic applications for DUB modulators in areas with significant unmet medical needs. Ubiquigent is committed to generating intellectual property through its innovative drug discovery programs, which include optimizing compounds that target the ubiquitin cascade.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.

Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, based in Stirling, United Kingdom. Established in 2011 to address the growing global demand for niche sterile manufacturing, the company provides filling and finishing services tailored to biotechnology and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis differentiates itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. By maintaining high standards of regulatory compliance, Symbiosis supports the evolving needs of its clients in the pharmaceutical sector.

Eagle Genomics is an enterprise software solutions company focused on managing and analyzing genomics and life sciences data. Its suite of products helps life science companies maximize the value of their research and development data by transforming data sets into actionable assets, thereby improving productivity and reducing costs and time in research processes. The company's platform offers an intuitive approach for curating, integrating, sharing, and analyzing scientific data, addressing the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech. With a unique combination of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics is well-positioned to tackle the complexities of data management in the genomics era, providing clarity on the value of digital assets and the return on information.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services for pharmaceutical and bioscience clients globally. Established in 2015, the company provides a range of preclinical screening services, with a focus on ion channel screening, cardiac safety profiling, neuroscience assays, and translational assays. Metrion's platform offers skilled electrophysiology services in various formats, supporting medicinal chemistry optimization. The organization employs flexible business models, allowing clients to choose between fee-for-service and collaborative options, as well as access to integrated drug discovery services tailored to the specific needs of each program.

Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market. We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.

BioSystems Technology focuses on developing alternative research models to meet scientific needs while reducing regulatory burdens and ethical concerns related to mammalian use. Founded by an infectious disease research fellow and a professor of molecular pathogenicity at the University of Exeter, the company specializes in creating models for microbiological research on fungal and bacterial pathogens. These innovative research models facilitate drug discovery and toxicity testing, allowing scientists to achieve rapid and reproducible results in their studies.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Activirosomes develops effective, safe and affordable vaccines and virotherapies.

Axitan develops a microalgae-production platform for the development of novel and safe products. Axitan is an algal biotechnology that facilitates a cost effective transition away from conventional antibiotics within the animal agriculture industry. Axitan aims to tackle some of the industries main challenges by applying algal biotechnology to deliver innovative products that support production, focusing on improving yield, quality and profitability, and being sustainable and resource efficient.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Eagle Genomics is an enterprise software solutions company focused on managing and analyzing genomics and life sciences data. Its suite of products helps life science companies maximize the value of their research and development data by transforming data sets into actionable assets, thereby improving productivity and reducing costs and time in research processes. The company's platform offers an intuitive approach for curating, integrating, sharing, and analyzing scientific data, addressing the challenges faced by industries such as pharmaceuticals, consumer goods, and agri-tech. With a unique combination of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics is well-positioned to tackle the complexities of data management in the genomics era, providing clarity on the value of digital assets and the return on information.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

Jellagen is a Med-Tech company specializing in high-grade native collagen sourced from jellyfish. This unique collagen is utilized for a range of applications in tissue engineering, regenerative medicine, stem cell research, and various cell culture processes. Jellagen provides its products in both solution and powder forms, ensuring batch-to-batch consistency that is beneficial for research and medical applications. By offering non-mammalian collagen, the company enables medicinal researchers to conduct in-house research and development, supporting the creation of innovative medical devices and advancing new methods for wound management and tissue engineering.

Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs. Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

LIFNano Therapeutics, established in 2013 as a spin-out from the University of Cambridge, is a clinical-stage company dedicated to the development of targeted therapies for neurodegenerative diseases, particularly multiple sclerosis. The company specializes in utilizing nanotechnology to deliver the biologic Leukaemia Inhibitory Factor (LIF), aiming to repair damaged tissues, including neurons in the brain and spinal cord. By focusing on natural treatment options, LIFNano Therapeutics seeks to provide innovative solutions for patients suffering from multiple sclerosis and other inflammatory diseases affecting the brain and immune system.

Oxford Genetics Ltd. is a UK-based biotechnology company that specializes in synthetic biology, focusing on DNA design, protein expression optimization, and cell line development technologies and services. The company offers a variety of plasmid products, including CRISPR plasmids, reporter genes, and viral vectors, which are used for various research and production applications. All products are designed to be free of intellectual property restrictions. Oxford Genetics provides its offerings through a global distribution network, serving customers in countries such as the United States, Canada, Germany, and Japan, while also enabling online purchases. Founded in 2011 and headquartered in Begbroke, the company has established a strategic partnership with The Native Antigen Company Ltd. to enhance its capabilities in the biotechnology sector.

Sarissa Biomedical, Ltd. specializes in the development and production of innovative biosensors aimed at measuring neuroactive chemicals for research and clinical diagnostic purposes. The company focuses on creating minimally invasive, microelectrode electrochemical sensors that accurately measure purines and other neurochemicals, serving as indicators of neurological activity and disorders. These biosensors are suitable for both in vitro and in vivo studies. Additionally, Sarissa Biomedical is developing a hand-held point-of-care diagnostic device that utilizes finger-prick blood samples to identify individuals experiencing strokes. Founded in 2002 and based in Coventry, the United Kingdom, Sarissa Biomedical markets its products in various regions, including the United Kingdom, United States, Canada, and Japan.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Videregen Limited is a regenerative medicine company based in Liverpool, United Kingdom, focused on developing organ replacement products to combat the chronic shortage of organs for transplantation. Established in 2011 as a spin-out from the Northwick Park Institute of Medical Research, the company specializes in creating biological scaffolds for organ regeneration, particularly targeting trachea, small bowel, and liver replacements. Utilizing decellularized organ scaffolds, Videregen's technology enables the seeding of these scaffolds with a patient’s own stem cells, resulting in personalized, non-immunogenic organ replacements. The company aims to pioneer commercially available organ replacement products, addressing critical health challenges and enhancing patient quality of life while potentially reducing healthcare costs.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, that specializes in designing and licensing synthetic antibody libraries and display technologies for antibody discovery. The company offers several systems, including the llamdA System for single-domain antibodies, the Xab System for human antibody fragments, and the 4D Fab System for synthetic human antibodies. Additionally, Isogenica provides peptide and scaffold platforms to facilitate the development of therapeutic peptides aimed at treating diseases. Its proprietary vitro display technology, known as CIS display, is employed to discover biologically active peptides, proteins, and antibodies. The company's innovative small-format antibodies can be utilized to create bispecific and multi-specific biotherapeutics, enhancing targeted drug delivery in applications such as antibody-drug conjugates and cell and gene therapies. Established in 1998 and originally named Pharmacophorix Limited, Isogenica serves pharmaceutical and biotechnology sectors, contributing significantly to advancements in medical research and therapeutic development.